Whalesbook
THE SEAMLESS LINK
The reported net loss and revenue dip underscore significant pressures on Piramal Pharma's financial performance, stemming from specific customer-driven destocking and operational hurdles at its facilities. This downturn contrasts with broader positive trends observed in biopharma funding and M&A activity within the sector.
The Core Catalyst
Piramal Pharma Limited announced a consolidated net loss of ₹136.2 crore for the third quarter of fiscal year 2026, a dramatic reversal from a ₹3.7 crore profit recorded in the same period last year. Revenue from operations saw a 2.9% year-on-year decline, settling at ₹2,139.90 crore, though it marked a 4.7% sequential increase. The company's earnings before interest, taxes, depreciation, and amortization (EBITDA) fell sharply by 42% year-on-year to ₹197.20 crore, with the EBITDA margin contracting to 9.1% from previous fiscal year levels. These results were impacted by ₹41 crore in exceptional items, including ₹26 crore for gratuity and leave encashment adjustments and ₹15 crore from a CDMO customer settlement. Despite the headline loss, the stock saw a mixed reaction on January 29, 2026; shares rose by approximately 4% to ₹163.20, as investors focused on the sequential improvement in revenue and EBITDA, along with recovery signals. Significant trading volume accompanied this movement, with over 17.7 million shares changing hands.
The Analytical Deep Dive
The pharmaceutical CDMO sector is showing tentative signs of recovery, bolstered by an increase in biopharma funding in the latter half of calendar year 2025, which was notably higher than the first half and the prior year's second half. Furthermore, M&A activity within the US healthcare space has seen an uptick. Competitors like Dr. Reddy's reported revenue growth in their Q3 FY26 results, with their CDMO arm contributing to novel drug manufacturing. In contrast, Piramal Pharma’s CDMO segment revenue declined 9% year-on-year, heavily influenced by inventory destocking from a key customer and operational issues at its Lexington facility. Regulatory delays affecting inhalation anesthesia exports from the Digwal facility also presented challenges. Historically, Piramal Pharma's stock has underperformed, declining 33.60% over the past year. The company's price-to-earnings (P/E) ratio is currently negative due to the reported losses, trading at approximately ₹153.69 on January 29, 2026, near its 52-week low of ₹148.30, and has a market capitalization around ₹20,400 crore.
The Future Outlook
Management anticipates that the current financial pressures may persist through fiscal year 2026, with a broader recovery expected from fiscal year 2027. Brokerage firm Choice International has revised its earnings estimates downward for FY26 and FY27 by 2% and 2.9% respectively, cut its valuation multiple by 10%, and maintained a 'Reduce' rating with a target price of ₹160. This cautious stance contrasts with a broader analyst consensus, where 9 analysts have issued a 'Strong Buy' recommendation with an average target price of ₹234.9. Piramal Pharma itself points to encouraging early indicators, including a significant increase in requests for proposals (RFPs) and order inflows since October 2025, driven by improved US biopharma funding and increased M&A. The company is proceeding with a US$90 million investment to expand its Lexington and Riverview facilities and has acquired the Kenalog brand, signalling commitment to future growth. Management expects the historically strong fourth quarter to bolster results, with ongoing investments in capacity and product expansion.